

Glucagon-Like Peptide-1 Receptor Agonists Added to Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Historical Cohort Study Using the Diabetes Study From the Center of Tokyo Women's Medical University (DIACET)

メタデータ	言語: 出版者: 東京女子医科大学学会 公開日: 2024-01-12 キーワード (Ja): キーワード (En): 作成者: BABAZONO, Tetsuya, MURATA, Hidekazu, SATO, Manaka, TAKEUCHI, Masakazu メールアドレス: 所属:
URL	http://hdl.handle.net/10470/0002000052

Tokyo Women's Medical University Journal

Glucagon-Like Peptide-1 Receptor Agonists Added to Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Historical Cohort Study Using the Diabetes Study From the Center of Tokyo Women's Medical University (DIACET)

Tetsuya Babazono¹, Hidekazu Murata¹, Manaka Sato², Masakazu Takeuchi²

¹Division of Diabetology and Metabolism, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan

²Japan Drug Development & Medical Affairs, Eli Lilly Japan K.K., Kobe, Japan

Author for correspondence: sato_manaka@lilly.com

Supplementary Table 1. Definition of time points for clinical measures.

Time point	Date of measurement falls within the period:
0 months	From index date – 45 days to index date + 45 days
3 months	From index date + 46 days to index date + 135 days
6 months	From index date + 136 days to index date + 225 days
9 months	From index date + 226 days to index date + 315 days
12 months	From index date + 316 days to index date + 405 days

The index date was the date when an individual was first prescribed a glucagon-like peptide-1 receptor agonist as add-on to a sodium-glucose cotransporter 2 inhibitor that they had been prescribed for ≥ 3 months. If there were multiple values within each time window, the value from closest to the nominal time point was used. If there were multiple values from a single day, the average of these values was used.